Products
Azerutamig Biosimilar Bispecific Antibody (NKG2D × HER2) for Research
Cat No.: GMP-Bios-INN-1091
Anti-KLRK1/NKG2D/CD314 therapeutic antibody (Pre-made Azerutamig biosimilar,Bispecific Mixed mAb and scFv-CH2-CH3) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Azerutamig (development code DF-1001) is a bispecific antibody targeting NKG2D (KLRK1) and HER2 (ERBB2). It is developed by Dragonfly Therapeutics and Gilead Sciences for solid tumours, breast cancer, non-small cell lung cancer. It is in Phase II clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1091-1mg | 1mg | |
| GMP-Bios-INN-1091-10mg | 10mg | |
| GMP-Bios-INN-1091-100mg | 100mg | |
| GMP-Bios-INN-1091-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Azerutamig biosimilar, Bispecific Mixed mAb and scFv-CH2-CH3, Anti-KLRK1/NKG2D/CD314;ERBB2/CD340/HER2 Antibody: Anti-CD314/NKG2D/KLRK1/NKG2-D type II integral membrane protein therapeutic antibody |
| INN Name | Azerutamig |
| Target | KLRK1/NKG2D/CD314;ERBB2/CD340/HER2 |
| Format | Bispecific Mixed mAb and scFv-CH2-CH3 |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1;G1 |
| VD LC | Kappa;Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None;None |
| 99% SI Structure | None;6bi0:HL:IM/4hkz:BA/6mh2:BA:DC/5xhg:DC:BA/1n8z:BA/6bi2:HL:IM/1fvc:BA:DC/6bhz:HL:IM/6oge:ED/7mn8:DC/7t97:HL:AB:CD:EF/7t99:HL:AB:CD:EF/4ub0:HL/5xhf:BA:DC/8ti4:HL/8tjf:HL:AB/8pwh:BA/8q6j:BA |
| 95-98% SI Structure | None;1fve:BA:DC/4x4x:AB:CD/5tdn:BA:DC/6bgt:BA/7kbp:CC/7t98:AB:HL/5tdn:BA:DC/1fvd:BA:DC/5tdp:BA:DC/4x4y:CD:AB/5tdo:BA:DC/6dn0:CD:AB/3be1:HL/3bdy:HL |
| Year Proposed | 2024 |
| Year Recommended | na |
| Companies | Dragonfly Therapeutics;Gilead Sciences |
| Conditions Approved | na |
| Conditions Active | Solid tumours;Breast cancer;Non-small cell lung cancer |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
